Clinical trials: First Relapse
Advanced Solid Tumor, Adult Disease
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Adult Disease, Lung Cancer
- Trial name
- ANV419-001 (NCT04855929)
- Testing
- ANV419, Ipilimumab
- Where
- 5 sites in Spain, Switzerland and 1 more
- Volunteers
- 55 people
- Sponsor
- Anaveon AG
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Solid Tumor, Advanced Solid Tumor
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Parts 1 and 2 The primary purpose of this study is to understand the safety of NL-201 when given intravenously as monotherapy in patients with advanced cancer to evaluate tolerability and to identify a recommended dose and…
- Trial name
- NCT04659629
- Testing
- NL-201, Pembrolizumab Injection [Keytruda]
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 59 people
- Sponsor
- Neurogene Inc.
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
The goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vaccine (DC/AML fusion vaccine) and standard of care decitabine and…
- Trial name
- NCT07374029
- Testing
- DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- David Avigan
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
This Research study is being done to characterize the safety, tolerability, and preliminary antitumor activity of the NEXI-001 T cell product (a new experimental therapy), which contains populations of CD8+ T cells targeting…
- Trial name
- NCT04284228
- Testing
- Infusion of NEXI-001 T Cells
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- NexImmune Inc.
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Trial name
- NCT01053494
- Testing
- massage therapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Glioblastoma Multiforme, Cognition Disorders
Bevacizumab and Lomustine for Recurrent GBM
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Glioblastoma Multiforme, Cognition Disorders, Disability Evaluation
- Trial name
- NCT01290939
- Testing
- bevacizumab, lomustine, DNA methylation analysis
- Where
- 2 sites in Netherlands
- Volunteers
- 592 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with…
- Trial name
- NCT06419634
- Testing
- BMS-986497, Azacitidine, Venetoclax
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 34 people
- Sponsor
- Bristol-Myers Squibb
Hodgkin Lymphoma
Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of BV as a single agent in elderly patients at first relapse or with primary refractory HL.
- Trial name
- FIL_BVHD01 (NCT02227433)
- Testing
- Brentuximab Vedotin
- Where
- 6 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Leukemia
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002499
- Testing
- asparaginase, cytarabine, daunorubicin hydrochloride
- Where
- Argentina
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Fever, Sweats, and Hot Flashes, Infection
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00020865
- Testing
- cefepime hydrochloride, levofloxacin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Leukemia
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00096135
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- 153 sites in United States, Australia and 3 more
- Volunteers
- 168 people
- Sponsor
- Children's Oncology Group
Glioblastoma
A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)
This is a Phase II, open-label, multicenter, randomized, non comparative study consisting of two concurrent single-arms. Approximately 160 subjects will be randomized in a 1:1 ratio to Arm 1 (bevacizumab alone) or Arm 2…
- Trial name
- BRAIN (NCT00345163)
- Testing
- bevacizumab, irinotecan
- Volunteers
- 167 people
- Sponsor
- Genentech, Inc.
B-Cell Non-Hodgkin Lymphoma
A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This is an open-label, first-in-human dose escalation and dose expansion Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HP-002 in patients with relapsed or refractory…
- Trial name
- NCT07658352
- Testing
- HP-002
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Shanghai Helioson Pharmaceutical Co., Ltd.
Mantle Cell Lymphoma
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL
This is a prospective, multicenter phase II trial designed to evaluate the safety and activity of the combination of Bendamustine, Lenalidomide and Rituximab (R2-B) in patients with first relapsed/refractory mantle cell lymphoma…
- Trial name
- R2-B (NCT01737177)
- Testing
- Bendamustine, Lenalidomide, Rituximab
- Where
- 43 sites in Italy
- Volunteers
- 42 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Bladder Hyperactivity
Secondary Bilateral Sacral Nerve Stimulation in Overactive Bladder Patients
Unilateral sacral neuromodulation (SNM) has emerged as a valuable treatment for patient with low urinary tract dysfunction when failure or bad tolerance to anticholinergic treatment for overactive bladder.
- Trial name
- NEUROBIL (NCT01960270)
- Testing
- Device: INTERSTIM II
- Where
- 12 sites in France
- Volunteers
- 34 people
- Sponsor
- University Hospital, Rouen
Anxiety Disorder, Cancer Survivor
Quality of Life in Younger Leukemia and Lymphoma Survivors
RATIONALE: Collecting information about the effect of hematologic cancer and its treatment on quality of life may help doctors learn more about the disease and plan the best treatment.
- Conditions
- Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia
- Trial name
- NCT00956475
- Testing
- telephone-based intervention, questionnaire administration, assessment of therapy complications
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Case Comprehensive Cancer Center
DLBCL, High-grade B-cell Lymphoma (HGBCL)
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20): The dose schedule…
- Conditions
- DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
- Trial name
- EPCORE™ NHL-1 (NCT03625037)
- Testing
- Epcoritamab
- Where
- 85 sites in United States, Australia and 13 more
- Volunteers
- 666 people
- Sponsor
- Genmab
Acute Myeloid Leukemia
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This first-in-human (FIH) clinical trial is a Phase 1/1b, open-label, sequential-group, dose-escalation and cohort expansion study evaluating the safety, PK, PD, and antitumor activity of FLX925 in subjects with relapsed or…
- Trial name
- NCT02335814
- Testing
- FLX925
- Where
- 12 sites in United States
- Volunteers
- 51 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological…
- Conditions
- Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
- Trial name
- NCT05086315
- Testing
- SAR443579
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 101 people
- Sponsor
- Sanofi